BioSpace News Archive

BrainChip Holdings Ltd, the world’s first commercial producer of ultra-low power neuromorphic AI IP, announced that Chief Development Officer Anil Mankar will present “System-Level Advances in Neuromorphic Performance, Efficiency, Configurability and Scalability” at the Linley Fall Processor Conference 2022 in the Hyatt Regency Hotel in Santa Clara, California, November 1 at 10 a.m. PDT.

Phathom Pharmaceuticals, Inc. announced that detailed results from an investigational Phase 2 study evaluating the efficacy of vonoprazan in non-erosive gastroesophageal reflux disease and other data will be presented at the American College of Gastroenterology 2022 Annual Scientific Meeting, being held October 21-26 in Charlotte, NC.

LAXAI Inc. announced that it has received a growth capital investment from SIGNET Healthcare Partners, a New York-based healthcare private equity firm.

AGTC announced that it has entered into a definitive agreement pursuant to which a newly established portfolio company of Syncona Limited, will acquire AGTC, through a tender offer, for approximately $23.5 million in cash at the closing of the transaction plus potential future aggregate cash payments of up to $50.0 million pursuant to contingent value rights.

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced that it is developing the MEVION S250-FIT Proton Therapy System™ with HYPERSCAN® Pencil Beam Scanning.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announces the presentation of safety and efficacy data from its open-label Phase 3 ECOSPOR IV extension study evaluating investigational oral microbiome therapeutic SER-109 for the prevention of rCDI at the IDWeek 2022 and American College of Gastroenterology 2022 Annual Meetings.

Vaxcyte, Inc. announced it will hold a webcast and conference call tomorrow, October 24, 2022, at 8:00 a.m. Eastern Time to provide topline results from its Phase 1/2 proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine, in healthy adults aged 18-64.

Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., and Myovant Sciences announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.

The Biotechnology Innovation Organization, Developing Countries Vaccine Manufacturers’ Network and the International Federation of Pharmaceutical Manufacturers and Associations have been key players in the historic effort to scale up the manufacturing of COVID-19 vaccines.